Xeris Bags Us Approval For Cushings Syndrome Drug Recorlev

Xeris Biopharma On Thursday Announced That The Fda Approved The Cortisol Synthesis Inhibitor Recorlev (Levoketoconazole) To Treat Endogenous Hypercortisolaemia In Adults With Cushing'S Syndrome For Whom Surgery Is Not An Option Or Has Not Been Curative. Ceo Paul Edick Said The Decision "Reinforces The Value That We Saw In Acquiring Strongbridge Biopharma'S Attractive Rare Disease Portfolio," A Deal Worth About $267 Million That Was Finalised In October.According To Xeris, The Filing Was Supported By Data From Two Phase Iii Trials That Evaluated A Combined Study Population Of 166 Patients That Is Representative Of The Adult Drug-Treated Us Population With Cushing'S Syndrome. Both The Sonics And Logics Trials Met Their Primary And Key Secondary Endpoints.Specifically, In The Sonics Study, Recorlev Demonstrated A Significant Normalisation Rate Of Urinary-Free Cortisol At Six Months Of Maintenance Therapy Without A Dose Increase. Meanwhile, Xeris Said Logics Confirmed The Efficacy And Safety Of Recorlev In Normalising And Maintaining Therapeutic Response Compared With Placebo."With This Approval, [Our]

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!